AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
Go back to AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections| (NASDAQ: AZRX) | Delayed: 3.45 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.45 | 52 Week High | $5.60 | |||
| Open | $10.00 | 52 Week Low | $3.98 | |||
| Day High | $3.45 | P/E | N/A | |||
| Day Low | $3.45 | EPS | $0.00 | |||
| Volume | 39,332 | |||||
| Pre-Paid Legal Services, Inc. (NASDAQ: PPD) | Delayed: 47.30 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $47.30 | 52 Week High | $68.66 | |||
| Open | $47.30 | 52 Week Low | $44.05 | |||
| Day High | $47.30 | P/E | 7.11 | |||
| Day Low | $47.30 | EPS | $6.65 | |||
| Volume | 20,772 | |||||
